IncellDx
11.06.2013 15:14
---------------------------------------------------------------------------
MENLO PARK, Calif., 2013-06-11 15:14 CEST (GLOBE NEWSWIRE) --
IncellDx announced today that it has executed an agreement with Kindstar
Global, the largest esoteric diagnostic testing service in China, to offer its
proprietary laboratory test for the detection of oncogenic HPV E6, E7 mRNA in
China. According to the Company, it believes that this agreement will greatly
augment its business presence in Asia.
This test is based upon IncellDx's advanced molecular diagnostic technology for
quantifying specific biomarkers that have been associated with an increased
risk of progression to cervical cancer, and will broaden Kindstar's current
offerings to physicians and hospitals managing diseases associated with women's
health. Kindstar will be the first reference laboratory in China to offer this
test.
Measuring the potential oncogenic activity of the human papillomavirus (HPV) in
infected cervical cells, this novel technology functions by detecting and
quantifying the expression of viral oncogenes responsible for triggering
progression to cervical cancer, resulting in a higher specificity that existing
tests lack.
'Offering this cutting-edge molecular technology to Chinese physicians not only
builds our women's health platform, it enhances Kindstar's leading position in
the fastest growing market in the world,' Kindstar founder and CEO Shiang Huang
said.
Bruce K. Patterson MD, founder and CEO of IncellDx, commented, 'The high level
of specificity our technology produces not only has a significant, positive
economic impact on healthcare delivery costs by potentially reducing the number
of unnecessary colposcopy/biopsies, but additionally improves patient care by
eliminating unnecessary concerns associated with some current results. We are
pleased that our partnership with Kindstar will provide better healthcare
outcomes for women in China.'
About IncellDx, Inc.
IncellDx, Inc. is a molecular diagnostics company dedicated to the detection
and monitoring of life threatening diseases such as cervical cancer, breast
cancer, HIV/AIDs, hepatitis, and organ transplant rejection. For more
information, please visit www.incelldx.com.
CONTACT: Tara Mackay - Investor Relations Coordinator
201-791-2600 x8750
News Source: NASDAQ OMX
11.06.2013 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: IncellDx
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9902652257
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-News: IncellDx Signs Deal With Kindstar Global to Offer Novel HPV Technology in China for Cervical Cancer Screening
| Source: EQS Group AG